CCI gives nod to Torrent-Elder Pharma deal Illustrative image – not actual.

The Competition Commission of India (CCI) has given approval to Torrent Pharma's proposed acquisition of Elder Pharma's formulations business in India and Nepal.


The acquisition will be valued at Rs 2,000 crore and will help Torrent enter new categories as well as expand operations in segments such as women's healthcare and pain management.


As per CCI, the proposed combination is not likely to have any significant, adverse effect on competition in India. CCI had asked the firms to provide clarification and justification on certain aspects of Non-Compete Obligations entered into between the two companies.


In response to that, both the companies, while providing clarification, had also proposed certain modifications, which were approved by CCI. The modifications include reduction of the duration of the 'Non-Compete Obligations' for the primary therapeutic areas, from five years to four years.


 

← All latest storiesBack to top →